
David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
David McIntosh, Chair of the UK Plasma Action Alliance (UKPA), reposted from Global Plasma Supply, on an emerging fight on Linkedin:
“The post here below is worth reposting daily, until the WHO, the European Blood Alliance, the International Plasma and Fractionation Association and a host of other misguided organisations drop their antiquated, unethical and utterly counter-productive opposition to Voluntary Reasonably Compensated Donation (VRCD) of human plasma.
Those who foster – and spread – baseless fears about the ‘dangers’ and ‘evils’ of large scale VRCD collection systems are
a) arguing against the system that is the prime global life-saver in the plasma-derived medicines field – currently four times more effective than the unpaid systems;
and
b) they are inhibiting, globally, the development of the increased VRCD systems that are so badly needed to deliver to patients the medicines they need.
The result …. ? …. millions of patients left untreated …. untold suffering … and millions of avoidable deaths.
Why …? … just because some well-meaning but utterly misguided zealots believe, and preach, that VRCD is ‘wrong’.
The hell it is!
It’s a life-saver!
AND, lest there be any doubt about this, everyone needs to be aware that some 80% of patients in the World today who suffer from ailments that can be, and should be, treated by plasma-derived medicines – 80% – are getting little or no such medicine at all. The paid-v-unpaid donation debate is not just a waste of time. It’s a deplorable waste of lives.
Please let’s stop all the nonsense and get on with the job – saving lives through effective plasma collection and supply – globally – via VRCD -VOLUNTARY REASONABLY COMPENSATED DONATION.”
Global Plasma Supply shared on LinkedIn:
”PAID or UNPAID — Lives Are Still Being Lost.
Let’s get one thing straight.
While the world debates how donors give, patients are still waiting. Still suffering. Still dying.
We hear the same tired argument over and over again:
“Paid plasma programs will kill altruism.”
Wrong.
- Proven wrong across Canada, the U.S., Germany, Austria, Hungary, and beyond.
- The data is clear: plasma centers don’t reduce whole blood donations — they increase them.
- 2020 study: for every 100 additional plasma donations, blood banks saw 8–10 extra whole blood units.
- Meta-analyses show no motivational crowd-out effect with incentives.
- EU nations with paid plasma systems have higher blood donation rates than many of those without.
Truth bomb: We’re not running out of altruism.
We’re running out of capacity and boldness.
So why are we still stuck arguing over T-shirts vs stipends?
Global Plasma Supply LTD stands for life.
We believe in both red cell donors and plasma donors.
We believe in choice, in new systems, and in ethical, evidence-based expansion.
We don’t just build plasma centers.
We build bridges between donation types.
We raise awareness in new communities.
We paint the ceiling of healthcare with both colors — red and gold.
Because the goal isn’t how it’s given.
It’s that it’s given — before it’s too late.”
Stay updated on the emerging topics in the field of transfusion medicine with Hemostasis Today.
-
Aug 13, 2025, 09:21VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
-
Aug 13, 2025, 06:44Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
-
Aug 13, 2025, 05:41ISTH 2025 Recorded Sessions Now Available on ISTH Academy
-
Aug 13, 2025, 01:39Radoslaw Kaczmarek: Challenges Limiting Gene Therapy Use in Hemophilia
-
Aug 12, 2025, 20:03David McIntosh Urges WHO, the European Blood Alliance, the International Plasma and Fractionation Association to Stop Opposition to VRCD
-
Aug 13, 2025, 16:24Giuseppe Lippi on Laboratory Diagnostics for Immediate Management of Acute Bleeding
-
Aug 13, 2025, 06:13Pip Nicolson: Understanding VITT From COVID-19 Vaccines
-
Aug 13, 2025, 05:23Baseline Hemoglobin Predicts Outcomes in Acute VTE: Low Hb Linked to Higher Bleeding, Ischemia and Mortality Risk
-
Aug 13, 2025, 04:13Lindsey George on Gene Therapy Transforming Hemophilia Care
-
Aug 13, 2025, 02:26Case Report Alert: Basilar Artery Occlusion in IgA-APS
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman
-
Aug 13, 2025, 10:25Joshua Muia on His HTRS Leadership Role Impact
-
Aug 11, 2025, 05:16Andreas Calatzis: Any Information on Soviet Thrombelastographs?
-
Aug 9, 2025, 15:36NBCA: Blood Clot Survivor Runs 2025 NYC Marathon with Team Stop the Clot
-
Aug 8, 2025, 18:33Hemophilia Alliance during Tennessee Hemophilia and Bleeding Disorders Foundation Annual Meeting 2025